The Gut–Brain Axis: Can Probiotics Really Affect Mood?

The idea that the bacteria in your gut could nudge your mood sounds like a stretch — until you look at how much signalling actually runs between the two. The gut–brain axis is real and well established as a communication system; the open question is how far we can usefully steer it with a daily capsule. This is the most emerging topic on the site, and we want to be honest about that: the science is genuinely promising and biologically plausible, but the human trial base is still thin, and much of it is in people with a clinical diagnosis rather than in the general population. Here is what is actually known.

A two-way conversation

The gut and brain are in constant contact along several routes: the vagus nerve, the immune system, hormones of the stress (HPA) axis, and a stream of chemical messengers produced in the gut itself. A striking share of the body’s serotonin is made by cells in the gut wall, and the trillions of bacteria living there influence that chemistry, along with other neuroactive molecules such as short-chain fatty acids and GABA.

So the wiring for a gut-to-mood link clearly exists. The harder question is whether changing the bacteria — by swallowing specific live strains — produces a change in mood that is large enough, and reliable enough, to matter in everyday life.

What “psychobiotics” means

Researchers coined the term psychobiotics for specific bacterial strains shown, in studies, to influence stress, mood or anxiety markers. The crucial word is specific. A psychobiotic effect, where it has been demonstrated, belongs to a named strain at a studied dose — not to “probiotics” as a category, and not to whichever product happens to advertise the biggest colony-forming-unit (CFU) number. Two products can both say “probiotic” on the label and contain entirely different organisms with entirely different (or no) evidence behind them.

That single fact should shape how you read any probiotic-for-mood claim: ask which strain, and which study.

The strains that have actually been studied

A small number of formulations account for most of the human mood research. It is worth naming them precisely, because the marketing around this category often blurs them together.

Lactobacillus helveticus R0052 + Bifidobacterium longum R0175. This two-strain combination (developed by Lallemand Health Solutions and marketed under names such as Cerebiome) is the most-studied psychobiotic pairing for mood. In a foundational 2011 study, Messaoudi and colleagues reported anxiety-reducing effects in rats and, in a separate group of healthy human volunteers taking around 3 billion CFU per day for 30 days, improvements in measures of psychological distress versus placebo. A companion paper that year reported benefits on stress-related symptoms, with a notable effect in volunteers who started with lower stress-hormone levels.

That early work is genuinely encouraging — but it is also where honesty matters. A later, well-conducted 2017 trial by Romijn and colleagues gave the same R0052/R0175 combination to people specifically selected for low mood and found no significant benefit over placebo on mood, stress or anxiety. A promising early signal that does not replicate in a more targeted sample is exactly the pattern that should keep expectations measured.

Ecologic Barrier (a separate, multi-strain formulation). This is a different product — a nine-strain blend from Winclove (including Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37 and others), not the R0052/R0175 pair, and the two are sometimes wrongly conflated. In a 2015 trial, Steenbergen and colleagues found that four weeks of this blend reduced cognitive reactivity to sad mood — essentially, the tendency for a low mood to spiral into rumination and negative thinking — in healthy young adults, with the strongest effects on rumination and aggressive thoughts. A later imaging follow-up using the same product did not find effects on emotional brain measures, which again argues for cautious interpretation.

The pattern across these is consistent: small studies, often in healthy or sub-clinical volunteers, with some positive signals and some null results, and very few large, long, replicated trials.

How strong is the overall evidence?

When you pool the trials, a recurring theme appears. A 2019 meta-analysis by Liu, Walsh and Sheehan looked across 34 prebiotic and probiotic trials and found that who was studied mattered enormously: effects were moderate in people with a clinical diagnosis but close to negligible in community samples without one. In other words, the clearest benefits show up in people who are already unwell, while the evidence for lifting mood in generally healthy people is much weaker.

More recent reviews echo this. A 2024 strain-specific meta-analysis (Goh and colleagues, 12 RCTs, around 700 participants) found measurable but variable benefits and emphasised that effects are strain-dependent rather than general. Across this literature, two limitations come up again and again: most trials are small and short, and the heterogeneity between them is high. That is the signature of a field that is promising but early — not one that has settled.

This is why we rate the gut-brain probiotic area as emerging, and why a probiotic is best thought of as a low-risk experiment to run alongside the basics (sleep, movement, fibre-rich diet, social connection), not as a mood treatment.

Typical use and how to read a label

If you want to try a studied formulation, the practical guidance is straightforward. Match the strain, not just the species or the CFU count: the evidence belongs to specific strain designations like R0052, R0175 or the W-numbered Ecologic Barrier strains. Check that the label lists strain-level identifiers and guarantees the CFU count through the end of shelf life, not just at manufacture. Most mood trials ran for around four weeks, so give any trial a few weeks before judging it. Take it consistently, ideally as directed on the product.

Cautions

Probiotics are generally well tolerated in healthy people; the most common complaints are short-lived bloating or digestive changes as your gut adjusts. The important exception is anyone who is immunocompromised, seriously ill, or has a central venous line — for them, live-organism supplements can carry real risk, and a doctor should be consulted first. If you are pregnant, breastfeeding or managing a chronic condition, check with a clinician before starting. And if low mood is the reason you are here, a probiotic is not a substitute for professional support — see our crisis and professional support resources.

Frequently asked questions

Can probiotics improve your mood? Some specific strains have shown mood or stress benefits in trials, but the effect is modest, strain-specific, and clearest in people who already have a clinical diagnosis. In generally healthy people the evidence is weaker. We rate it as emerging.

What is a psychobiotic? A psychobiotic is a specific probiotic strain that has been shown to influence mood, stress or anxiety. The key is that the effect is tied to the named strain and dose studied — not to probiotics in general.

Which probiotic strains are best for mood? The most-studied are the Lactobacillus helveticus R0052 + Bifidobacterium longum R0175 combination and the multi-strain Ecologic Barrier blend. “Best” overstates it — these are simply the ones with the most human data, and even there the results are mixed.

How long do probiotics take to affect mood? Most mood trials ran for around four weeks, so that is a reasonable window to allow before drawing any conclusion.

Does a higher CFU count mean a better mood probiotic? No. The evidence is about specific strains at the doses studied, not about maximising CFUs. A very high CFU count of an unstudied strain tells you nothing about mood.

Supplements mentioned

• Gut-brain probiotic — full profile, studied strains and evidence tier — our product page covers strain selection and labels in more detail.

Sources

• Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. British Journal of Nutrition, 2011;105(5):755–764. doi:10.1017/S0007114510004319
• Messaoudi M, Violle N, Bisson J-F, et al. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes, 2011;2(4):256–261. doi:10.4161/gmic.2.4.16108
• Romijn AR, Rucklidge JJ, Kuijer RG, Frampton C. A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression. Australian & New Zealand Journal of Psychiatry, 2017;51(8):810–821. doi:10.1177/0004867416686694 — found no significant benefit in a low-mood sample.
• Steenbergen L, Sellaro R, van Hemert S, Bosch JA, Colzato LS. A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain, Behavior, and Immunity, 2015;48:258–264. doi:10.1016/j.bbi.2015.04.003
• Liu RT, Walsh RFL, Sheehan AE. Prebiotics and probiotics for depression and anxiety: a systematic review and meta-analysis of controlled clinical trials. Neuroscience & Biobehavioral Reviews, 2019;102:13–23. doi:10.1016/j.neubiorev.2019.03.023 — effects larger in clinical than community samples.
• Goh KK, et al. Strain-specific effects of probiotics on depression and anxiety: a systematic review and meta-analysis. Gut Pathogens, 2024;16:46. doi:10.1186/s13099-024-00634-8

This article is for general information and is not medical advice. It describes evidence-aware support, not treatment for depression or any diagnosed condition. Always consult a qualified healthcare professional before starting a supplement, especially if you are immunocompromised, pregnant or managing a health condition. See our medical disclaimer and support resources.